RESUMEN
PURPOSE: To assess the expression of genes that are relevant to pyroptosis and the relationship between these genes and prognosis in uterine corpus endometrial carcinoma (UCEC). METHODS: The research identifies 16 pyroptosis regulators with different expressions in normal endometrium and UCEC. In accordance with the differentially expressed genes (DEGs), the various kinds of UCEC are classified into two sub-types. With the help of the Cancer Genome Atlas (TCGA), the prognostic value of all pyroptosis-related genes for survival was assessed, and a multigene model has constructed accordingly. Ten genes were modeled by applying the minimum criteria for determining risk score selection (LASSO) Cox regression method. Meanwhile, by referring to the TCGA atlas, UCEC patients were divided into the high- and low-risk subgroups. The effects of the gene with significant differences on the proliferation of two cancer cells were also verified. RESULTS: The survival rate of UCEC cases with higher risk was higher than that with lower risk (P < 0.001). Through the median risk score of TCGA atlas, UCEC cases were ranked as patients with higher risk and patients with lower risk. The low risk has a significant relationship with the prolongation of overall survival (OS) (p = 0.001) in the low-risk subgroup. Moreover, the KEGG and gene ontology (GO) enrichment models indicated that among the patients in the high-risk subgroup, their immune-related genes were concentrated but with decreased immune status. CONCLUSION: The apoptosis-related genes are crucial for the immunity of tumors and may forecast the prognosis of UCEC.
Asunto(s)
Carcinoma Endometrioide , Neoplasias Endometriales , Femenino , Humanos , Piroptosis/genética , Pronóstico , Apoptosis , Factores de Riesgo , Neoplasias Endometriales/genéticaRESUMEN
ABSTRACT This study aimed to describe a Bacillus subtilis expression system based on genetically modified B. subtilis. Abaecin, an antimicrobial peptide obtained from Apis mellifera, can enhance the effect of pore-forming peptides from other species on the inhibition of bacterial growth. For the exogenous expression, the abaecin gene was fused with a tobacco etch virus protease cleavage site, a promoter Pglv, and a mature beta-glucanase signal peptide. Also, a B. subtilis expression system was constructed. The recombinant abaecin gene was expressed and purified as a recombinant protein in the culture supernatant. The purified abaecin did not inhibit the growth of Escherichia coli strain K88. Cecropin A and hymenoptaecin exhibited potent bactericidal activities at concentrations of 1 and 1.5 µM. Combinatorial assays revealed that cecropin A and hymenoptaecin had sublethal concentrations of 0.3 and 0.5 µM. This potentiating functional interaction represents a promising therapeutic strategy. It provides an opportunity to address the rising threat of multidrug-resistant pathogens that are recalcitrant to conventional antibiotics.(AU)
Asunto(s)
Bacillus subtilis/clasificación , Bacillus subtilis/genética , AntiinfecciososRESUMEN
ABSTRACT This study aimed to describe a Bacillus subtilis expression system based on genetically modified B. subtilis. Abaecin, an antimicrobial peptide obtained from Apis mellifera, can enhance the effect of pore-forming peptides from other species on the inhibition of bacterial growth. For the exogenous expression, the abaecin gene was fused with a tobacco etch virus protease cleavage site, a promoter Pglv, and a mature beta-glucanase signal peptide. Also, a B. subtilis expression system was constructed. The recombinant abaecin gene was expressed and purified as a recombinant protein in the culture supernatant. The purified abaecin did not inhibit the growth of Escherichia coli strain K88. Cecropin A and hymenoptaecin exhibited potent bactericidal activities at concentrations of 1 and 1.5 µM. Combinatorial assays revealed that cecropin A and hymenoptaecin had sublethal concentrations of 0.3 and 0.5 µM. This potentiating functional interaction represents a promising therapeutic strategy. It provides an opportunity to address the rising threat of multidrug-resistant pathogens that are recalcitrant to conventional antibiotics.
Asunto(s)
Péptidos Catiónicos Antimicrobianos/genética , Péptidos Catiónicos Antimicrobianos/metabolismo , Bacillus subtilis/genética , Vectores Genéticos/genética , Proteínas de Insectos/genética , Proteínas de Insectos/metabolismo , Antibacterianos/aislamiento & purificación , Antibacterianos/metabolismo , Antibacterianos/farmacología , Péptidos Catiónicos Antimicrobianos/aislamiento & purificación , Péptidos Catiónicos Antimicrobianos/farmacología , Bacillus subtilis/metabolismo , Escherichia coli/efectos de los fármacos , Escherichia coli/crecimiento & desarrollo , Expresión Génica , Vectores Genéticos/metabolismo , Proteínas de Insectos/aislamiento & purificación , Proteínas de Insectos/farmacología , Ingeniería de Proteínas , Transporte de Proteínas , Proteínas Recombinantes/genética , Proteínas Recombinantes/aislamiento & purificación , Proteínas Recombinantes/metabolismo , Proteínas Recombinantes/farmacologíaRESUMEN
This study aimed to describe a Bacillus subtilis expression system based on genetically modified B. subtilis. Abaecin, an antimicrobial peptide obtained from Apis mellifera, can enhance the effect of pore-forming peptides from other species on the inhibition of bacterial growth. For the exogenous expression, the abaecin gene was fused with a tobacco etch virus protease cleavage site, a promoter Pglv, and a mature beta-glucanase signal peptide. Also, a B. subtilis expression system was constructed. The recombinant abaecin gene was expressed and purified as a recombinant protein in the culture supernatant. The purified abaecin did not inhibit the growth of Escherichia coli strain K88. Cecropin A and hymenoptaecin exhibited potent bactericidal activities at concentrations of 1 and 1.5µM. Combinatorial assays revealed that cecropin A and hymenoptaecin had sublethal concentrations of 0.3 and 0.5µM. This potentiating functional interaction represents a promising therapeutic strategy. It provides an opportunity to address the rising threat of multidrug-resistant pathogens that are recalcitrant to conventional antibiotics.